ASMBASSEMBLY BIOSCIENCES, INC.

Nasdaq assemblybio.com


$ 14.60 $ 0.20 (1.38 %)    

Friday, 23-Aug-2024 15:30:44 EDT
QQQ $ 479.76 $ 5.15 (1.08 %)
DIA $ 411.97 $ 4.35 (1.07 %)
SPY $ 562.00 $ 5.91 (1.06 %)
TLT $ 98.37 $ 0.64 (0.65 %)
GLD $ 231.99 $ 2.65 (1.16 %)
$ 14.61
$ 14.60 x 202
-- x --
-- - --
$ 7.69 - $ 20.04
20,829
na
92.71M
$ 0.69
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 03-28-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-09-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 03-22-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-11-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 02-25-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-05-2020 06-30-2020 10-Q
18 05-08-2020 03-31-2020 10-Q
19 03-04-2020 12-31-2019 10-K
20 11-07-2019 09-30-2019 10-Q
21 08-05-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 02-28-2019 12-31-2018 10-K
24 11-08-2018 09-30-2018 10-Q
25 08-08-2018 06-30-2018 10-Q
26 05-07-2018 03-31-2018 10-Q
27 03-08-2018 12-31-2017 10-K
28 11-01-2017 09-30-2017 10-Q
29 08-09-2017 06-30-2017 10-Q
30 05-08-2017 03-31-2017 10-Q
31 03-02-2017 12-31-2016 10-K
32 11-09-2016 09-30-2016 10-Q
33 08-09-2016 06-30-2016 10-Q
34 05-10-2016 03-31-2016 10-Q
35 03-11-2016 12-31-2015 10-K
36 11-09-2015 09-30-2015 10-Q
37 08-13-2015 06-30-2015 10-Q
38 05-08-2015 03-31-2015 10-Q
39 03-12-2015 12-31-2014 10-K
40 11-17-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 assembly-biosciences-q2-eps-198-beats-223-estimate-sales-853m-beat-596m-estimate

Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(1.98) per share which beat the analyst consensus estimate of ...

 hc-wainwright--co-reiterates-neutral-on-assembly-biosciences

HC Wainwright & Co. analyst Ed Arce reiterates Assembly Biosciences (NASDAQ:ASMB) with a Neutral.

 assembly-biosciences-announces-126m-in-equity-financings-for-the-issuance-of-634500-shares-of-its-common-stock-and-warrants-to-armistice-capital-llc

— Funding supports advancement of antiviral portfolio, including four candidates in clinical development, and extends cash runw...

 hc-wainwright--co-reiterates-neutral-on-assembly-biosciences

HC Wainwright & Co. analyst Ed Arce reiterates Assembly Biosciences (NASDAQ:ASMB) with a Neutral.

 assembly-biosciences-doses-first-participant-in-phase-1ab-trial-of-hsv-inhibitor-abi-5366

– Phase 1a study portion of single ascending dosing in healthy participants will inform the development of ABI-5366 with interi...

 assembly-biosciences-q1-eps-166-beats-324-estimate

Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(1.66) per share which beat the analyst consensus estimate of ...

 hc-wainwright--co-reiterates-neutral-on-assembly-biosciences

HC Wainwright & Co. analyst Ed Arce reiterates Assembly Biosciences (NASDAQ:ASMB) with a Neutral.

 assembly-biosciences-q4-eps-174-beats-288-estimate-sales-716m

Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(1.74) per share which beat the analyst consensus estimate of ...

 assembly-biosciences-announces-effective-date-of-february-9-2024-for-1-for-12-reverse-stock-split

– Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 – SOUTH SAN FRANCISCO, Cal...

 assembly-biosciences-on-jan-11-notified-indiana-university-that-co-decided-to-terminate-exclusive-license-agreement-dated-september-3-2023

-SEC Filing

 assembly-biosciences-provided-an-outline-of-the-anticipated-milestones-and-progress-for-its-clinical-pipeline-during-2024

Four development candidates anticipated to be in the clinic by the end of 2024, reflecting expansion of R&D portfolio acros...

 why-icosavax-shares-are-trading-higher-by-around-45-here-are-20-stocks-moving-premarket

Shares of Icosavax, Inc. (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION